2001
Improvement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy
Semba R, Shah N, Vlahov D. Improvement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 315-319. PMID: 11317071, DOI: 10.1097/00126334-200104010-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnemiaAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBaltimoreBody Mass IndexCD4 Lymphocyte CountChronic DiseaseFemaleHemoglobinsHIV InfectionsHIV-1HumansLongitudinal StudiesMaleMultivariate AnalysisPrevalenceSex FactorsSubstance Abuse, IntravenousViral LoadConceptsInjection drug usersPlasma HIV loadActive antiretroviral therapyAntiretroviral therapyHIV loadOpportunistic infectionsCopies/Mean decreaseDrug usersHIV-positive injection drug usersPotent antiretroviral therapyImprovement of anemiaBody mass indexIncrease of hemoglobinAntiretroviral medicationsHIV infectionMass indexControl subjectsOverall prevalenceChronic diseasesAnemiaNutritional statusMean increaseMultivariate analysisHAART
1999
Self-Reported Bacterial Infections Among Women with or at Risk for Human Immunodeficiency Virus Infection
Flanigan T, Hogan J, Smith D, Schoenbaum E, Vlahov D, Schuman P, Mayer K. Self-Reported Bacterial Infections Among Women with or at Risk for Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1999, 29: 608-612. PMID: 10530455, DOI: 10.1086/598641.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCD4 cell countImmunodeficiency virus infectionBacterial infectionsRecent pneumoniaVirus infectionCell countHIV-negative womenHIV-seropositive womenUrinary tract infectionInjection drug useLogistic regression analysisSelf-reported pneumoniaCross-sectional analysisSeronegative womenTract infectionsHIV infectionDrug useLifetime historyInfectionPneumoniaMajor causeWomenRegression analysisCell categoriesReduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation.
Dean M, Jacobson L, McFarlane G, Margolick J, Jenkins F, Howard O, Dong H, Goedert J, Buchbinder S, Gomperts E, Vlahov D, Oppenheim J, O'Brien S, Carrington M. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Research 1999, 59: 3561-4. PMID: 10446961.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsB-LymphocytesCase-Control StudiesChemokine CCL5Cohort StudiesGene FrequencyGenetic Predisposition to DiseaseHIV-1HumansLymphoma, AIDS-RelatedMalePoint MutationReceptors, CCR5RiskSarcoma, KaposiSequence DeletionTetradecanoylphorbol AcetateWhite PeopleConceptsNon-Hodgkin lymphomaB cellsAIDS lymphomasCCR5 geneRisk of NHLMulticenter AIDS Cohort StudyCCR5 ligand RANTEST-cell declineAIDS Cohort StudyCCR5-Delta32 alleleB-cell lymphomaCase-control analysisCCR5-Delta32 mutationChemokine receptor genesCCR5 chemokine receptor geneTime of infectionLigand RANTESTime AIDSCohort studyOpportunistic infectionsAIDS patientsCommon malignancyKaposi's sarcomaNHL casesProliferative responseCell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men
Lyles C, Graham N, Astemborski J, Vlahov D, Margolick J, Saah A, Farzadegan H. Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. European Journal Of Epidemiology 1999, 15: 99-108. PMID: 10204638, DOI: 10.1023/a:1007556327269.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCause of DeathCD4 Lymphocyte CountCohort StudiesConfidence IntervalsDisease ProgressionFemaleFollow-Up StudiesHIV InfectionsHIV-1Homosexuality, MaleHumansImmunocompromised HostLeukocytes, MononuclearMalePredictive Value of TestsProportional Hazards ModelsRisk FactorsSubstance Abuse, IntravenousSurvival AnalysisSurvival RateViral LoadViremiaConceptsHIV-1 viral loadViral loadHomosexual menRisk groupsHIV-1Relative hazardDrug usersPeripheral blood mononuclear cellsMicroculture techniqueBlood mononuclear cellsInjection drug usersHIV-1 progressionInitial CD4Clinical progressionMononuclear cellsNegative culturesPredictive valueSurvival analysisBacterial infectionsTotal participantsAIDSProgressionInfectious unitsCells/Death
1998
Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease
Sterling T, Moore R, Graham N, Astemborski J, Vlahov D, Chaisson R. Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease. AIDS 1998, 12: 1451-1457. PMID: 9727565, DOI: 10.1097/00002030-199812000-00006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAntibiotic ProphylaxisAntitubercular AgentsCD4 Lymphocyte CountCohort StudiesFemaleHumansMaleMiddle AgedMycobacterium avium ComplexMycobacterium avium-intracellulare InfectionMycobacterium tuberculosisProspective StudiesRisk FactorsSubstance Abuse, IntravenousTuberculosisConceptsM. tuberculosis infectionM. avium complex diseaseMycobacterium tuberculosis infectionDisseminated MACTuberculosis infectionExtrapulmonary tuberculosisDrug useLow CD4 cell levelsProspective observational cohort studyAdult HIV clinicIntravenous Experience cohortPrior opportunistic infectionsCD4 cell levelsObservational cohort studyLogistic regression analysisALIVE cohortAntibiotic prophylaxisMAC prophylaxisAntiretroviral therapyCD4 lymphocytesHIV clinicMAC diseaseActive tuberculosisCohort studyOpportunistic infectionsPrognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count
Vlahov D, Graham N, Hoover D, Flynn C, Bartlett J, Margolick J, Lyles C, Nelson K, Smith D, Holmberg S, Farzadegan H. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count. JAMA 1998, 279: 35-40. PMID: 9424041, DOI: 10.1001/jama.279.1.35.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBiomarkersBlack or African AmericanCD4 Lymphocyte CountDisease ProgressionFemaleHIV-1HumansMalePrognosisProportional Hazards ModelsProspective StudiesRegression AnalysisRNA, ViralSubstance Abuse, IntravenousSurvival AnalysisViral LoadConceptsInfectious disease deathsInjection drug usersPlasma viral loadViral loadDisease deathsCell countDrug usersPrognostic indicatorHuman immunodeficiency virus type 1 (HIV-1) viral loadAfrican American injection drug usersPlasma HIV-1 RNAHIV-1 viral loadInfectious diseasesClinical AIDS diagnosisLevels of CD4Kaplan-Meier analysisHIV-1 RNAPrognosis of personsPowerful prognostic informationProportional hazards modelCases of AIDSGood predictive valueCell count measurementsMedian followCohort study
1996
Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease
Graham N, Galai N, Nelson K, Astemborski J, Bonds M, Rizzo R, Sheeley L, Vlahov D. Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease. JAMA Internal Medicine 1996, 156: 889-894. PMID: 8774208, DOI: 10.1001/archinte.1996.00440080089010.Peer-Reviewed Original ResearchConceptsM avium complexMycobacterial diseaseTuberculosis incidenceAvium complexCutaneous anergyIsoniazid chemoprophylaxisIsoniazid prophylaxisPreventive therapyRisk factorsIncidence rateCD4 lymphocyte cell countProspective observational cohort studyPPD-positive patientsTwice-weekly isoniazidWeeks of therapyObservational cohort studyLymphocyte cell countsMonths of diagnosisOverall incidence rateAnnual incidence ratePopulation-based dataStrong risk factorTuberculin-positive subjectsMycobacterium avium complexTuberculin-positive individuals
1994
Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users.
Caiaffa W, Vlahov D, Graham N, Astemborski J, Solomon L, Nelson K, Muñoz A. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. American Journal Of Respiratory And Critical Care Medicine 1994, 150: 1493-1498. PMID: 7952605, DOI: 10.1164/ajrccm.150.6.7952605.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsCocaineCohort StudiesCrack CocaineFemaleHIV SeronegativityHIV SeropositivityHIV-1HumansImmunocompromised HostIncidenceMaleMarijuana SmokingOdds RatioPneumoniaPneumonia, PneumocystisRisk FactorsSmokingSubstance Abuse, IntravenousSubstance-Related DisordersConceptsInjection drug usersPneumocystis carinii pneumoniaHIV-seropositive injection drug usersBacterial pneumoniaOdds ratioCarinii pneumoniaCigarette smokingFirst episodeDrug usersIllicit drugsSeropositive injection drug usersCD4 lymphocyte countHIV-seronegative subjectsMedical record reviewHuman immunodeficiency virusCells/Conditional logistic regressionSeronegative subjectsCohort studyLymphocyte countRecord reviewImmunodeficiency virusControl subjectsRisk factorsUnivariate analysisMycarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus
Herskowitz A, Wu T, Willoughby S, Vlahov D, Ansari A, Beschorner W, Baughman K. Mycarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. Journal Of The American College Of Cardiology 1994, 24: 1025-1032. PMID: 7930193, DOI: 10.1016/0735-1097(94)90865-6.Peer-Reviewed Original ResearchConceptsLeft ventricular dysfunctionCongestive heart failureEndomyocardial biopsy samplesVentricular dysfunctionHeart failureNew York Heart Association functional class IIIBiopsy samplesGlobal left ventricular hypokinesiaSevere left ventricular dysfunctionUnexplained left ventricular dysfunctionHuman immunodeficiency virus type 1Global left ventricular dysfunctionImmunodeficiency virus type 1Cardiotropic viral infectionCardiotropic virus infectionLeft ventricular hypokinesiaOpportunistic infectious agentFunctional class IIIHuman immunodeficiency virusHIV-1 gene sequencesNumber of patientsTwo-dimensional echocardiographyMajor histocompatibility class IVirus type 1Antisense riboprobesComparison of clinical manifestations of HIV infection between male and female injecting drug users
Vlahov D, Muñoz A, Solomon L, Astemborski J, Lindsay A, Anderson J, Galai N, Nelson K. Comparison of clinical manifestations of HIV infection between male and female injecting drug users. AIDS 1994, 8: 819-824. PMID: 7916193, DOI: 10.1097/00002030-199406000-00015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAIDS-Related Opportunistic InfectionsCD4-Positive T-LymphocytesCross-Sectional StudiesFemaleHIV InfectionsHumansLeukocyte CountMaleMiddle AgedSex FactorsSubstance Abuse, IntravenousConceptsCD4 cell countHIV infectionCell countDrug usersMedian CD4 cell countPosterior cervical lymph nodesAIDS-free HIVHIV-seropositive menCervical lymph nodesHIV-seronegative controlsDiagnosis of AIDSShortness of breathPhysical examination findingsHIV-seropositive participantsSymptoms of diarrheaHIV serologyGenital herpesLymphocyte countLymph nodesMedian ageSimilar CD4Examination findingsClinical manifestationsClinical symptomsConstitutional signs
1993
Bacterial Pneumonia in Adult Populations with Human Immunodeficiency Virus (HIV) Infection
Caiaffa W, Graham N, Vlahov D. Bacterial Pneumonia in Adult Populations with Human Immunodeficiency Virus (HIV) Infection. American Journal Of Epidemiology 1993, 138: 909-922. PMID: 8256779, DOI: 10.1093/oxfordjournals.aje.a116812.Peer-Reviewed Original ResearchConceptsBacterial pneumoniaRisk factorsHuman immunodeficiency virus (HIV) infectionEffectiveness of chemoprophylaxisImmunodeficiency virus infectionRecurrent bacterial pneumoniaHuman immunodeficiency virusEfficacy of interventionsPneumonia ratesImmunodeficiency syndromeImmunodeficiency virusClinical trialsVaccine interventionsVirus infectionEpidemiologic studiesClinical practicePneumoniaAdult populationDiagnostic algorithmFuture interventionsInterventionHIVSuch interventionsPopulationChemoprophylaxis